Xin Lang Cai Jing·2025-12-08 04:42Core Viewpoint - BeiGene is expected to achieve sustainable revenue growth through the launch of new products, with a revenue target of $5.1 billion to $5.3 billion deemed highly achievable [1] Group 1: Revenue Growth Potential - Analysts from Daiwa Capital Markets believe that BeiGene's revenue target is likely to be met, supported by its global operational platform which will enhance operational efficiency and cash generation capabilities [1] - The company's cancer therapy Brukinsa is projected to continue boosting global sales in the coming years due to its best-in-class characteristics and expanding market penetration [1] Group 2: Financial Outlook - From 2025 onwards, BeiGene is expected to achieve positive profits and positive free cash flow, attributed to a more diversified revenue structure and improving profit margins [1] - Daiwa Capital Markets has assigned a "Buy" rating to the stock, with a target price set at HKD 252.00 [1]